Sugi Predict

Sugi Predict / Compounds / SCHEMBL7922005

SCHEMBL7922005

SCHEMBL7922005

O=C(Cl)c1cc(F)c(Cl)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 4/20 0.42
▸ CES1 P23141 4/20 0.42
▸ ALDH1A1 P00352 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ HDAC1 Q13547 3/20 0.34
▸ HDAC6 Q9UBN7 3/20 0.34
▸ KCNQ3 O43525 5/20 0.34
▸ KCNQ2 O43526 5/20 0.34
▸ KCNE1 P15382 4/20 0.34
▸ KCNQ1 P51787 4/20 0.34
▸ KEAP1 Q14145 1/20 0.33
▸ NFE2L2 Q16236 1/20 0.33
▸ KCNQ5 Q9NR82 2/20 0.33
▸ TPMT P51580 1/20 0.32
▸ TTR P02766 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL193908 0.82 CES2 (0.64) CES2CES1ALDH1A1ALOX15HDAC1
SCHEMBL1001361 0.80 TPMT (0.54) CES2CES1ALDH1A1ALOX15KEAP1
SCHEMBL7922027 0.79 CES2 (0.48) CES2CES1ALDH1A1ALOX15HDAC1
SCHEMBL24670816 0.78 CES2 (0.41) CES2CES1ALDH1A1ALOX15HDAC1
SCHEMBL11878100 0.78 HDAC1 (0.57) CES2CES1ALDH1A1ALOX15HDAC1
SCHEMBL23112583 0.78 CA5A (0.46) CES2CES1HDAC1HDAC6LMNA
SCHEMBL987144 0.78 HDAC1 (0.57) CES2CES1ALDH1A1ALOX15HDAC1
SCHEMBL5948933 0.76 CES2 (0.50) CES2CES1ALDH1A1ALOX15HDAC1
SCHEMBL31049040 0.76 CES2 (0.35) CES2CES1ALDH1A1ALOX15HDAC1
SCHEMBL11629278 0.76 CA1 (0.47) CES2CES1ALDH1A1HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3782994-B1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY INC (US) 2025-07-16 — — EP disclosed
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2025-03-20 — — US disclosed
CN-114716381-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-03-11 — — CN disclosed
CN-114605327-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-03-11 — — CN disclosed
CN-114573510-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-02-25 — — CN disclosed
US-12220401-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY, INC. (US) 2025-02-11 — — US disclosed
CN-114591242-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2025-01-07 — — CN disclosed
CN-114634447-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-11-15 — — CN disclosed
CN-113603645-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-10-29 — — CN disclosed
CN-113636978-B Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2024-10-29 — — CN disclosed
US-20190135762-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2019-05-09 — — US disclosed
US-20190000806-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2019-01-03 — — US disclosed
US-20180362512-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2018-12-20 — — US disclosed
EP-3390395-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS Loxo Oncology Inc. (US) 2018-10-24 — — EP disclosed
WO-2017103611-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS REDX PHARMA PLC (GB) 2017-06-22 — — WO disclosed
EP-1140735-A1 PREPARATION OF NUCLEAR CHLORINATED AROMATIC COMPOUNDS OCCIDENTAL CHEMICAL CORPORATION (US) 2001-10-10 — — EP disclosed
WO-2000040524-A1 PREPARATION OF NUCLEAR CHLORINATED AROMATIC COMPOUNDS OCCIDENTAL CHEMICAL CORPORATION (US) 2000-07-13 — — WO disclosed
US-5981789-A CHLORODENITRATING AROMATIC COMPOUNDS USING LESS CHLORINATING AGENT AND LOWER TEMPERATURES, THEN RECYCLING THE PRODUCT MIXTURE TO INCREASE THE YIELD OCCIDENTAL CHEMICAL CORPORATION (US) 1999-11-09 — — US disclosed
US-4704483-A FLUORINATION WITH POTASSIUM FLUORIDE OCCIDENTAL CHEMICAL CORPORATION (US) 1987-11-03 — — US disclosed
EP-0159388-A2 Preparation of nuclear chlorinated compounds OCCIDENTAL CHEMICAL CORPORATION (US) 1985-10-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12220401-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK CES2 2629/4885CES1 3013/4885ALDH1A1 4454/4885
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK CES2 2629/4885CES1 3013/4885ALDH1A1 4454/4885
US-20180362512-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK CES2 2629/4885CES1 3013/4885ALDH1A1 4454/4885
US-20190135762-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK CES2 2629/4885CES1 3013/4885ALDH1A1 4454/4885
US-20190000806-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK CES2 2629/4885CES1 3013/4885ALDH1A1 4454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.